The University of Chicago Header Logo
Last Name


Dorothy Hanck to Calcium Channel Blockers

This is a "connection" page, showing publications Dorothy Hanck has written about Calcium Channel Blockers.

Connection Strength
  1. Bergson P, Lipkind G, Lee SP, Duban ME, Hanck DA. Verapamil block of T-type calcium channels. Mol Pharmacol. 2011 Mar; 79(3):411-9.
    View in: PubMed
    Score: 0.429
  2. Edgerton GB, Blumenthal KM, Hanck DA. Inhibition of the activation pathway of the T-type calcium channel Ca(V)3.1 by ProTxII. Toxicon. 2010 Sep 15; 56(4):624-36.
    View in: PubMed
    Score: 0.415
  3. McNulty MM, Kyle JW, Lipkind GM, Hanck DA. An inner pore residue (Asn406) in the Nav1.5 channel controls slow inactivation and enhances mibefradil block to T-type Ca2+ channel levels. Mol Pharmacol. 2006 Nov; 70(5):1514-23.
    View in: PubMed
    Score: 0.317
  4. Freeze BS, McNulty MM, Hanck DA. State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel. Mol Pharmacol. 2006 Aug; 70(2):718-26.
    View in: PubMed
    Score: 0.312
  5. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, Hanck DA. Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct; 295(1):302-8.
    View in: PubMed
    Score: 0.211
  6. McNulty MM, Hanck DA. State-dependent mibefradil block of Na+ channels. Mol Pharmacol. 2004 Dec; 66(6):1652-61.
    View in: PubMed
    Score: 0.071
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.